Meymandi Simin Shamsi; Dabiri Shahriar; Maryam Iranpour; Maryam Khalili; Mahin Aflatoonian
Abstract
Background: Lichen planus (LP) is a common inflammatory skin disease. Pathogenesis of LP includes two possible mechanisms; related or unrelated to antigen. Regarding different clinical features of cutaneous and mucosal types of LP, for the first time, we decided to perform a qualitative and quantitative ...
Read More
Background: Lichen planus (LP) is a common inflammatory skin disease. Pathogenesis of LP includes two possible mechanisms; related or unrelated to antigen. Regarding different clinical features of cutaneous and mucosal types of LP, for the first time, we decided to perform a qualitative and quantitative study of immune cells in different types of cutaneous LP and in comparison with normal skin. Methods: A total of 88 specimens (60 cases of cutaneous LP, 28 cases of normal skin) were selected from 2016 to 2017 in Kerman, Iran. Evaluation of immune cells was carried out based on qualitative and quantitative analysis. These findings were statistically calculated by descriptive statistical tests including frequency and mean ± standard deviation. Quantitative data were analyzed by independent t-test, chi-square, and analysis of variance (ANOVA). Data were analyzed using SPSS16 (SPSS Inc., Chicago, IL, USA). A p value less than 0.05 was considered statistically significant. Results: Our study demonstrated that the mean number of immune cells was significantly higher in lichen planus group in comparison with the control group. Number and staining intensity of Langerhans cells (LCs) in the LP group were significantly greater in epidermal than dermal region. Mastocytes were located mostly within the deep dermis in the LP group. Hypertrophic and atrophic LP had the highest and the lowest number of immune cells (i.e., mastocytes, LCs, and CD3 positive cells), respectively, with a significant difference. Conclusion: Our study demonstrated that immune cells were seen in larger numbers in the hypertrophic type of cutaneous LP which is consistent with the chronicity of this disease.
Maryam Khalili; Mahin Aflatoonian; Alireza Zeinaddini; Rahim Ahmadi; Simin Shamsi Meymandi
Abstract
PHACES syndrome (Posterior Fossa Malformations, Hemangioma, Arterial Anomalies, Cardiac Defects and Coarctation of the Aorta, Eye Abnormalities, and Sternal Abnormalities or Ventral Developmental Defects) is a rare neurocutaneous syndrome, which characteristic feature is large segmental hemangioma. Extracutaneous ...
Read More
PHACES syndrome (Posterior Fossa Malformations, Hemangioma, Arterial Anomalies, Cardiac Defects and Coarctation of the Aorta, Eye Abnormalities, and Sternal Abnormalities or Ventral Developmental Defects) is a rare neurocutaneous syndrome, which characteristic feature is large segmental hemangioma. Extracutaneous involvement is an important cause of morbidity in this syndrome.Described below is an infant with large hemangiomatous lesions on the right side of the face, suprasternal notch, midline sternal defect and supraumbilical raphe. Based on the new consensus on the diagnostic criteria of PHACES syndrome, a definitive diagnosis of PHACES syndrome has been corroborated. Accordingly, our patient was analyzed with regards to other clinical features through magnetic resonance imaging of the head, neck and abdomen, all of which were normal. In echocardiography, the patient showed atrial septal defect, in addition to ipsilateral conductive hearing loss, contralateral cataract and Horner’s syndrome, which was reported only in very few cases. The clinical presentation of the present case was different from most previous reported ones, as segmental hemangioma in PHACES syndrome was, for the most part, located on the left side of the face and ocular involvement was predominantly reported ipsilateral to hemangiomatous lesion.
Simin Shamsi Meymandi; Manzumeh Shamsi Meymandi; Soodabeh Zandi; Shahriar Dabiri; Mahin Aflatoonian
Volume 14, Issue 2 , 2011, , Pages 42-47
Abstract
Background: Cutaneous leishmaniasis (CL) is a major world problem. Several types of treatment regimens have been suggested. Imiquimod demonstrated a leishmanicidal activity by increasing local cytokine production. The aim of this study was to determine the efficacy of topical 5% imiquimod with cryotherapy ...
Read More
Background: Cutaneous leishmaniasis (CL) is a major world problem. Several types of treatment regimens have been suggested. Imiquimod demonstrated a leishmanicidal activity by increasing local cytokine production. The aim of this study was to determine the efficacy of topical 5% imiquimod with cryotherapy vs. intralesional meglumine antimoniate (MA) in treatment of anthroponotic (dry type) CL. Method: This is a prospective, randomized, open trial study (from Iran) from September 2008 to September 2010, including 50 patients (25 patients in the combined imiquimod and cryotherapy group and 25 patients in the intralesional MA group). Patients were randomly assigned to receive combined cryotherapy biweekly with imiquimod three times per week or intralesional MA weekly until complete cure or up to 12 weeks, whichever earlier. The primary end point was clinical cure, defined as complete re-epitelialization of 100%, complete flattening of induration compared with baseline at weeks 2, 6, 12 and follow up were done 1, 2 and 3 months after complete cure. Results: 50 participants divided into 25 patients in group A and 25 patients in group B completed the study. Complete cure was 65.5% (16/24 patients) in group A and 83.3% (19/23 patients) in group B. No complication was detected in patients treated with MA. Pain and eczematous reaction were detected by 4 patients and local infection in 1 patient treated with imiquimod. Conclusion: Although Meguimine antimoniate seems to be a more effective therapy for cutaneous leishmaniasis, this study revealed no significant difference in clinical response between combination of imiquimod and cryotherapy with intralesional MA in patients with cutaneous leishmaniasis in an endemic area of L. tropica.